ASX - By Stock
|
AVR |
Re:
Cleveland Clinic has enrolled patients in EFS
|
|
redant
|
39 |
11K |
6 |
10/10/23 |
10/10/23 |
ASX - By Stock
|
39
|
11K
|
6
|
|
ASX - By Stock
|
AVR |
Re:
Cleveland Clinic has enrolled patients in EFS
|
|
redant
|
39 |
11K |
2 |
06/10/23 |
06/10/23 |
ASX - By Stock
|
39
|
11K
|
2
|
|
ASX - By Stock
|
PAB Medicine |
Re:
GENETAL
|
|
redant
|
74 |
37K |
6 |
05/10/23 |
05/10/23 |
ASX - By Stock
|
74
|
37K
|
6
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Anteris to Present at Cantor Healthcare Conference
|
|
redant
|
73 |
27K |
5 |
03/10/23 |
03/10/23 |
ASX - By Stock
|
73
|
27K
|
5
|
|
ASX - By Stock
|
ICN |
Re:
Ann: Appointment of Director and Resignation of Chairman
|
|
redant
|
44 |
13K |
0 |
01/10/23 |
01/10/23 |
ASX - By Stock
|
44
|
13K
|
0
|
|
ASX - By Stock
|
AVR |
Re:
Update on Edwards
|
|
redant
|
11 |
5.3K |
0 |
27/09/23 |
27/09/23 |
ASX - By Stock
|
11
|
5.3K
|
0
|
|
ASX - By Stock
|
AVR |
Update on Edwards
|
|
redant
|
11 |
5.3K |
0 |
27/09/23 |
27/09/23 |
ASX - By Stock
|
11
|
5.3K
|
0
|
|
ASX - By Stock
|
PAB |
Re:
Ann: Appendix 4E and 2023 Annual Report
|
|
redant
|
21 |
10K |
3 |
23/09/23 |
23/09/23 |
ASX - By Stock
|
21
|
10K
|
3
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Anteris to Present at Cantor Healthcare Conference
|
|
redant
|
73 |
27K |
1 |
22/09/23 |
22/09/23 |
ASX - By Stock
|
73
|
27K
|
1
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Anteris to Present at Cantor Healthcare Conference
|
|
redant
|
73 |
27K |
4 |
20/09/23 |
20/09/23 |
ASX - By Stock
|
73
|
27K
|
4
|
|
ASX - By Stock
|
TD1 |
Re:
Akili Latest
|
|
redant
|
14 |
6.8K |
2 |
19/09/23 |
19/09/23 |
ASX - By Stock
|
14
|
6.8K
|
2
|
|
ASX - By Stock
|
AVR |
Re:
AVR named Top Medtech Start up for 2023
|
|
redant
|
7 |
3.2K |
1 |
17/09/23 |
17/09/23 |
ASX - By Stock
|
7
|
3.2K
|
1
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Anteris to Present at Cantor Healthcare Conference
|
|
redant
|
73 |
27K |
5 |
15/09/23 |
15/09/23 |
ASX - By Stock
|
73
|
27K
|
5
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Anteris to Present at Cantor Healthcare Conference
|
|
redant
|
73 |
27K |
1 |
14/09/23 |
14/09/23 |
ASX - By Stock
|
73
|
27K
|
1
|
|
ASX - By Stock
|
AVR |
Re:
AVR named Top Medtech Start up for 2023
|
|
redant
|
7 |
3.2K |
7 |
13/09/23 |
13/09/23 |
ASX - By Stock
|
7
|
3.2K
|
7
|
|
ASX - By Stock
|
AVR |
Re:
2 DurAVR’s implanted in Dallas
|
|
redant
|
19 |
6.4K |
1 |
08/09/23 |
08/09/23 |
ASX - By Stock
|
19
|
6.4K
|
1
|
|
ASX - By Stock
|
AVR |
Re:
2 DurAVR’s implanted in Dallas
|
|
redant
|
19 |
6.4K |
7 |
08/09/23 |
08/09/23 |
ASX - By Stock
|
19
|
6.4K
|
7
|
|
ASX - By Stock
|
ICN |
Re:
Ann: Market Update - Extension of Hearing Date
|
|
redant
|
18 |
6.5K |
1 |
07/09/23 |
07/09/23 |
ASX - By Stock
|
18
|
6.5K
|
1
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Results of Meeting
|
|
redant
|
31 |
8.8K |
1 |
06/09/23 |
06/09/23 |
ASX - By Stock
|
31
|
8.8K
|
1
|
|
ASX - By Stock
|
AVR |
Re:
Anteris Technologies Ltd Extraordinary General Meeting Wednesday, 6 September 2023 at 10:00 AM (AEST).
|
|
redant
|
6 |
3.2K |
2 |
06/09/23 |
06/09/23 |
ASX - By Stock
|
6
|
3.2K
|
2
|
|
ASX - By Stock
|
AVR |
Re:
Eureka report
|
|
redant
|
56 |
19K |
3 |
01/09/23 |
01/09/23 |
ASX - By Stock
|
56
|
19K
|
3
|
|
ASX - By Stock
|
AVR |
Re:
Cheap takeover
|
|
redant
|
38 |
13K |
0 |
23/08/23 |
23/08/23 |
ASX - By Stock
|
38
|
13K
|
0
|
|
ASX - By Stock
|
AVR |
Re:
Cheap takeover
|
|
redant
|
38 |
13K |
5 |
22/08/23 |
22/08/23 |
ASX - By Stock
|
38
|
13K
|
5
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Exceptional Results in Second Valve-in-Valve Case
|
|
redant
|
42 |
13K |
9 |
16/08/23 |
16/08/23 |
ASX - By Stock
|
42
|
13K
|
9
|
|
ASX - By Stock
|
AVR |
Re:
FIH 12 mth results published in Heart Lung Circulation
|
|
redant
|
15 |
5.3K |
0 |
07/08/23 |
07/08/23 |
ASX - By Stock
|
15
|
5.3K
|
0
|
|
ASX - By Stock
|
PAB |
Re:
Ann: Appendix 4C - Quarterly - 30 June 2023
|
|
redant
|
25 |
9.0K |
1 |
06/08/23 |
06/08/23 |
ASX - By Stock
|
25
|
9.0K
|
1
|
|
ASX - By Stock
|
TD1 |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
redant
|
14 |
3.4K |
0 |
06/08/23 |
06/08/23 |
ASX - By Stock
|
14
|
3.4K
|
0
|
|
ASX - By Stock
|
ICN |
Re:
Ann: Market Update - Extension of Hearing Date
|
|
redant
|
18 |
6.5K |
1 |
02/08/23 |
02/08/23 |
ASX - By Stock
|
18
|
6.5K
|
1
|
|
ASX - By Stock
|
ICN |
Re:
Ann: Market Update - Extension of Hearing Date
|
|
redant
|
18 |
6.5K |
0 |
02/08/23 |
02/08/23 |
ASX - By Stock
|
18
|
6.5K
|
0
|
|
ASX - By Stock
|
PAB |
Re:
PAB Chart & TA
|
|
redant
|
348 |
131K |
1 |
01/08/23 |
01/08/23 |
ASX - By Stock
|
348
|
131K
|
1
|
|
ASX - By Stock
|
AVR |
Re:
EFS details posted to official US government site
|
|
redant
|
55 |
20K |
0 |
28/07/23 |
28/07/23 |
ASX - By Stock
|
55
|
20K
|
0
|
|
ASX - By Stock
|
PAB |
Re:
Ann: Application for quotation of securities - PAB
|
|
redant
|
24 |
5.6K |
4 |
27/07/23 |
27/07/23 |
ASX - By Stock
|
24
|
5.6K
|
4
|
|
ASX - By Stock
|
PAB |
Re:
Ann: Appendix 4C - Quarterly - 30 June 2023
|
|
redant
|
25 |
9.0K |
2 |
26/07/23 |
26/07/23 |
ASX - By Stock
|
25
|
9.0K
|
2
|
|
ASX - By Stock
|
AVR |
J & J Professes Voracious Appetite for Medtech M & A
|
|
redant
|
16 |
7.1K |
8 |
21/07/23 |
21/07/23 |
ASX - By Stock
|
16
|
7.1K
|
8
|
|
ASX - By Stock
|
AVR |
Re:
Top Ten
|
|
redant
|
3 |
1.6K |
1 |
17/07/23 |
17/07/23 |
ASX - By Stock
|
3
|
1.6K
|
1
|
|
ASX - By Stock
|
PAB |
Re:
PAB Chart & TA
|
|
redant
|
348 |
131K |
2 |
13/07/23 |
13/07/23 |
ASX - By Stock
|
348
|
131K
|
2
|
|
ASX - By Stock
|
AVR |
Top Ten
|
|
redant
|
3 |
1.6K |
17 |
13/07/23 |
13/07/23 |
ASX - By Stock
|
3
|
1.6K
|
17
|
|
ASX - By Stock
|
PAB |
Re:
PAB Chart & TA
|
|
redant
|
348 |
131K |
3 |
13/07/23 |
13/07/23 |
ASX - By Stock
|
348
|
131K
|
3
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Application for quotation of securities - AVR
|
|
redant
|
2 |
1.0K |
4 |
13/07/23 |
13/07/23 |
ASX - By Stock
|
2
|
1.0K
|
4
|
|
ASX - By Stock
|
ICN |
Re:
Ann: Quarterly Activities/Appendix 5B Cash Flow Report
|
|
redant
|
45 |
16K |
0 |
29/06/23 |
29/06/23 |
ASX - By Stock
|
45
|
16K
|
0
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Application for quotation of securities - AVR
|
|
redant
|
2 |
1.2K |
2 |
24/06/23 |
24/06/23 |
ASX - By Stock
|
2
|
1.2K
|
2
|
|
ASX - By Stock
|
ICN |
Re:
Ann: Quarterly Activities/Appendix 5B Cash Flow Report
|
|
redant
|
45 |
16K |
3 |
22/06/23 |
22/06/23 |
ASX - By Stock
|
45
|
16K
|
3
|
|
ASX - By Stock
|
ICN |
Re:
Ann: Quarterly Activities/Appendix 5B Cash Flow Report
|
|
redant
|
45 |
16K |
1 |
22/06/23 |
22/06/23 |
ASX - By Stock
|
45
|
16K
|
1
|
|
ASX - By Stock
|
ICN |
Re:
Ann: Quarterly Activities/Appendix 5B Cash Flow Report
|
|
redant
|
45 |
16K |
2 |
21/06/23 |
21/06/23 |
ASX - By Stock
|
45
|
16K
|
2
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Latest Patient Group Show Best Results to Date at 30 Days
|
|
redant
|
107 |
37K |
3 |
14/06/23 |
14/06/23 |
ASX - By Stock
|
107
|
37K
|
3
|
|
ASX - By Stock
|
PAB |
Re:
Ann: PAT-DX1 GLP toxicology reports received
|
|
redant
|
62 |
29K |
2 |
14/06/23 |
14/06/23 |
ASX - By Stock
|
62
|
29K
|
2
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Change of Director's Interest Notice
|
|
redant
|
13 |
3.9K |
7 |
02/06/23 |
02/06/23 |
ASX - By Stock
|
13
|
3.9K
|
7
|
|
ASX - By Stock
|
AVR |
Re:
AGM questions for submission to management
|
|
redant
|
37 |
15K |
2 |
26/05/23 |
26/05/23 |
ASX - By Stock
|
37
|
15K
|
2
|
|
ASX - By Stock
|
AVR |
Re:
Video discussion on EuroPCR2023 presentation
|
|
redant
|
12 |
4.0K |
0 |
23/05/23 |
23/05/23 |
ASX - By Stock
|
12
|
4.0K
|
0
|
|
ASX - By Stock
|
PAB |
Re:
Ann: Appendix 4C - Quarterly - 31 March 2023
|
|
redant
|
102 |
36K |
3 |
10/05/23 |
10/05/23 |
ASX - By Stock
|
102
|
36K
|
3
|
|